The insider sales are routine in size and timing (post-earnings blackout window opening). No bearish read-through, the COO's sale is likely diversification after the stock's recent volatility. Monitor for any larger insider sales or 10b5-1 plan adoption, but this cluster alone does not warrant action.
Drug in focus
RCKT drug pipeline →RP-A501
● Neutral Named in this insider cluster- Impact
- Phase
- Phase 2 (pivotal/registrational)
- Time to market
- If the pivotal Phase 2 trial succeeds, a BLA submission for accelerated approval could follow in 2028-2029, given the 12-month endpoint timeline with last patient dosed by mid-2027.
- Next catalyst
- None dated
What to watchWatch for updates on enrollment of the remaining 9 patients in the pivotal Phase 2 trial and any interim data presentations at medical conferences in 2027. The FDA alignment in September 2026 de-risked the regulatory path, but the stock near its 52-week low reflects lingering safety concerns and a long wait until topline data (likely 2028). KRESLADI commercial traction is a separate value driver that could support the stock in the interim.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 14 $3.47entry
- T+1 · 3mo ago −2.02%α −1.54% · $3.40
- T+5 · 3mo ago +1.15%α +2.52% · $3.51
- T+20 · 2mo ago −1.15%α +0.84% · $3.43
- T+60 · 8d ago −27.09%α −24.04% · $2.53
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Two insiders at Rocket Pharmaceuticals, including the COO, sold a combined $145K in open-market sales on August 11, 2026, just three days after the company reported a Q2 2026 GAAP net income of $123.2M driven by a $178.2M PRV sale. The sales are small relative to the $374M market cap (0.04%), and the cluster is not amplified per academic literature since insider sales are weak predictors. The trades likely reflect routine portfolio diversification following the positive earnings catalyst, not a bearish signal on fundamentals.
Key Financial Metrics
Key Facts
- COO Christopher Stevens sold 36,658 shares for $128K at $3.50/share on Aug 11, 2026
- Sarbani Chaudhuri sold 4,701 shares for $16K at $3.50/share on Aug 11, 2026
- Total insider sales of $145K represent 0.04% of RCKT's $374M market cap
- Sales occurred 3 days after Q2 2026 earnings release showing $123.2M net income and $283.7M cash runway into Q2 2028
Financial Impact
Insider sales of $145K are immaterial relative to $374M market cap (0.04%)
Risk Factors
- Insider sales could accelerate if stock rallies further
- No C-suite buys to offset the selling signal
- Small sample size (2 trades) limits statistical significance
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-RCKT-1786691343806 |
Track record
21 reports on RCKT
5 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +42.18% at T+20 after the Jun 12, 2026 report. 6 of 6 went positive at some point.
Filters
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $2.45 Now $2.16 −11.84% settles Dec 15
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $2.30 Now $2.16 −6.09% settles Dec 14
- Nov 12, 20264d ago Insider Cluster Neutral 3/10 Entry $2.30 Now $2.16 −6.09% settles Dec 14
- Nov 12, 20264d ago 8-K Neutral 5/10 Entry $2.30 Now $2.16 −6.09% settles Dec 14
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $2.53 Now $2.16 −14.62% settles Dec 8
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $2.53 Now $2.16 −14.62% settles Dec 8
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $2.44 Now $2.16 −11.29% settles Dec 4
- Oct 30, 202617d ago SC 13G/A Neutral 2/10 Entry $2.44 Now $2.16 −11.48% settles Nov 30
- Oct 6, 20265w ago 8-K Bullish 7/10 Entry $2.54 to $2.57 Now $2.16 −14.79% ▲ +1.38% +2.62% vs SPY
- Sep 15, 20268w ago 8-K Bullish 7/10 Entry $3.41 to $2.30 Now $2.16 −36.66% ▼ −32.55% −35.27% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers